NCT05504057

Antihistamines, Amantadine and Evolution of COVID-19

Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 140,660 (estimated)
• Sponsor: Consorci Sanitari de Terrassa · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Detailed description

BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection. OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19. METHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments. The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Antihistamine	Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
DRUG	Amantadine	Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Timeline

• Start date: 2020-03-01
• Primary completion: 2025-01-19
• Completion: 2028-02-24
• First posted: 2022-08-17
• Last updated: 2026-04-03

Locations

2 sites across 1 country: Spain

Regulatory

• FDA-regulated drug study